Athira Inks $4M FCA Deal Over Ex-CEO's Research Fraud

By Rae Ann Varona · January 6, 2025, 11:05 PM EST

Athira Pharma Inc. has agreed to pay $4 million to resolve allegations it used falsified academic research papers on neurological disorders like Alzheimer's to secure federal grants from the National Institute...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Case Information

Case Title

United States of America et al v. Athira Pharma Inc

Case Number

Court

Washington Western

Nature of Suit

Qui Tam (31 U.S.C. § 3729(a))

Date Filed

June 24, 2021

Recent Articles By Rae

December 20, 2024
Proskauer Beats DQ Bid In NJ Hospital Antitrust Fight
December 18, 2024
Pharma Trial Consultant To Pay SEC $3M Over Insider Trading
December 11, 2024
Split 9th Circ. Nixes Trump-Era Hospital Reimbursement Rule
December 10, 2024
Bristol-Myers Said To Renege On $450M Milestone Promise
December 03, 2024
US Claims Court Backs HHS Agency's $20.5M IT Deal Choice
November 20, 2024
CVS Can't Dodge Proposed Action Over 'Non-Drowsy' Claims
October 30, 2024
5th Circ. Keeps Most No Surprises Act Provisions Intact
October 08, 2024
Elanco Misled Investors About Dog Medicine Safety, Suit Says
October 04, 2024
DOJ Charges Execs, Sales Reps Over Texas 'Pill Mills' Sales
September 30, 2024
Calif. Sues Eureka Hospital For Denying Emergency Abortion